Nektar Therapeutics
455 Mission Bay Boulevard South
San Francisco, California 94158-2117
November 15, 2017
VIA EDGAR
Office of Healthcare and Insurance
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ibolya Ignat, Senior Staff Accountant
| Re: | Nektar Therapeutics |
| Form 10-K for the Fiscal Year Ended December 31, 2016 |
| Filed March 1, 2017 |
| File No. 000-24006 |
Dear Ms. Ignat:
We are in receipt of the letter from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) dated November 1, 2017, regarding the Annual Report on Form 10-K for the fiscal year ended December 31, 2016 (File No. 000-24006) filed by Nektar Therapeutics, a Delaware corporation (the “Company”), on March 1, 2017. We hereby respectfully request that the Commission grant an extension of the deadline for the Company to provide its response to the Staff’s comment in the letter to November 24, 2017.
If you have any questions regarding this request, please do not hesitate to contact the undersigned at (415) 482-5570.
| Sincerely, |
| /s/ Gil M. Labrucherie |
| Gil M. Labrucherie |
| Senior Vice President and Chief Financial Officer |
| cc: | Angela Connell, Accounting Branch Chief, Division of Corporation Finance |
| Jillian B. Thomsen, Senior Vice President, Finance and Chief Accounting Officer of Nektar Therapeutics |
| Mark A. Wilson, Vice President and General Counsel of Nektar Therapeutics |
| Sam Zucker, Esq., Sidley Austin LLP |